Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer

Biffi, Roberto; Fazio, Nicola; Luca, Fabrizio; Chiappa, Antonio; Andreoni, Bruno; Zampino, Maria Giulia; Roth, Arnaud; Schuller, Jan Christian; Fiori, Giancarla; Orsi, Franco; Bonomo, Guido; Crosta, Cristiano; Huber, Olivier

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer
Authors		Biffi, Roberto Fazio, Nicola Luca, Fabrizio Chiappa, Antonio Andreoni, Bruno Zampino, Maria Giulia Roth, Arnaud Schuller, Jan Christian Fiori, Giancarla Orsi, Franco Bonomo, Guido Crosta, Cristiano Huber, Olivier show all authors [1 - 13]
Published in		World Journal of Gastroenterology. 2010, vol. 16, no. 7, p. 868-874
Abstract		AIM: To investigate feasibility, morbidity and surgical mortality of a docetaxel-based chemotherapy regimen randomly administered before or after gastrectomy in patients suffering from locally-advanced resectable gastric cancer. METHODS: Patients suffering from locally-advanced (T3-4 any N M0 or any T N1-3 M0) gastric carcinoma, staged with endoscopic ultrasound, bone scan, computed tomography, and laparoscopy, were assigned to receive four 21 d/cycles of TCF (docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2) per day for days 1-14), either before (Arm A) or after (Arm B) gastrectomy. Operative morbidity, overall mortality, and severe adverse events were compared by intention-to-treat analysis. RESULTS: From November 1999 to November 2005, 70 patients were treated. After preoperative TCF (Arm A), thirty-two (94%) resections were performed, 85% of which were R0. Pathological response was complete in 4 patients (11.7%), and partial in 18 (55%). No surgical mortality and 28.5% morbidity rate were observed, similar to those of immediate surgery arm (P = 0.86). Serious chemotherapy adverse events tended to be more frequent in arm B (23% vs 11%, P = 0.07), with a single death per arm. CONCLUSION: Surgery following docetaxel-based chemotherapy was safe and with similar morbidity to immediate surgery in patients with locally-advanced resectable gastric carcinoma.
Keywords		Adult — Aged — Antineoplastic Combined Chemotherapy Protocols/adverse effects/ therapeutic use — Carcinoma/ drug therapy/mortality/pathology/ surgery — Chemotherapy, Adjuvant — Cisplatin/administration & dosage — Disease-Free Survival — Endosonography — Europe — Feasibility Studies — Female — Fluorouracil/administration & dosage — Gastrectomy/adverse effects/mortality — Humans — Laparoscopy — Male — Middle Aged — Neoadjuvant Therapy — Neoplasm Invasiveness — Neoplasm Staging — Radionuclide Imaging — Stomach Neoplasms/ drug therapy/mortality/pathology/ surgery — Taxoids/administration & dosage — Time Factors — Tomography, Spiral Computed — Treatment Outcome
Identifiers		PMID: 20143466
Full text		Article - Limited access to UNIGE Other version: http://www.wjgnet.com/1007-9327/index.jsp
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département de chirurgie
Research group		Groupe Roth Arnaud (oncologie) (285)
Citation (ISO format)		BIFFI, Roberto et al. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. In: World Journal of Gastroenterology, 2010, vol. 16, n° 7, p. 868-874. https://archive-ouverte.unige.ch/unige:20779